Everolimus

Red

Brand Name(s):Afinitor

Indication:Advanced renal cell carcinoma

Rationale:1,2,3,8

Considered:Jun-09

Review Date:Mar-22

Comments:
NICE TA432
Everolimus for advanced renal cell carcinoma after previous treatment
Feb 22
…………………………
1.1 Everolimus is not recommended for the second-line treatment of advanced renal cell carcinoma.
1.2 People currently receiving everolimus for the second-line treatment of advanced renal cell carcinoma should have the option to continue treatment until they and their clinician consider it appropriate to stop.
NICE Guidance TA219 April 2011